{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:30:54Z","timestamp":1791919854922,"version":"4.3.4"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012041","name":"Versus Arthritis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory disease belonging to the family of spondyloarthropathies (SpA). PsA commonly aggravates psoriasis of the skin and frequently manifests as an oligoarthritis with axial skeletal involvement and extraarticular manifestations including dactylitis, enthesitis, and uveitis. The weight of genetic predisposition to psoriasis and PsA is illustrated by the concordance rates in monozygotic twins which clearly demonstrate that genomics is insufficient to induce the clinical phenotype. The association of PsA with several single nucleotide polymorphisms (SNPs) at the IL23R locus and the involvement of Th17 cells in the immunopathogenesis of PsA clearly put the IL-23\/IL-17 axis in the spotlight. The IL-23 and IL-17 cytokines have a pivotal role in the chronic inflammation of the synovium in PsA and are also prominent in the skin lesions of those with PsA. In this review, we focus on the genetic association of the IL-23\/IL-17 axis with PsA and the contribution of these master cytokines in the pathophysiology of the disease, highlighting the main cell types incriminated in PsA and their specific role in the peripheral blood, lesional skin and joints of patients. We then provide an overview of the approved biologic drugs targeting the IL-23\/IL-17 axis and discuss the advantages of genetic stratification to enhance personalized therapies in PsA.<\/jats:p>","DOI":"10.3389\/fimmu.2020.596086","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T06:42:35Z","timestamp":1610001755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis"],"prefix":"10.3389","volume":"11","author":[{"given":"Matteo","family":"Vecellio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien Xanath","family":"Hake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connor","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Carena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Paul","family":"Wordsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheumat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The Epidemiology of Psoriatic Arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheumat Dis Clinics North Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","article-title":"The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications","volume":"5","author":"Marinoni","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"B4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.190119","article-title":"The Genetics of Psoriasis and Psoriatic Arthritis","volume":"95","author":"O\u2019Rielly","year":"2019","journal-title":"J Rheumatol Suppl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheumat Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa039","article-title":"Enthesitis in psoriatic arthritis (Part 1): pathophysiology","volume":"59","author":"Araujo","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39259","article-title":"Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases","volume":"68","author":"Scher","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B10","article-title":"The genetics of psoriatic arthritis: lessons from genome-wide association studies","volume":"10","author":"Bowes","year":"2010","journal-title":"Discov Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3528","article-title":"Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci","volume":"48","author":"Ellinghaus","year":"2016","journal-title":"Nat Genet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"iv58","DOI":"10.1093\/rheumatology\/keaa464","article-title":"Genetics and the axial spondyloarthritis spectrum","volume":"59","author":"Brown","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.23185","article-title":"Prevalence of malignancy in psoriatic arthritis","volume":"58","author":"Rohekar","year":"2008","journal-title":"Arthritis Rheumat"},{"key":"B14","first-page":"899","article-title":"Psoriatic arthritis criteria evaluation: CASPAR and Modified CASPAR","volume":"29","author":"Zlatkovic-Svenda","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu237","article-title":"Psoriatic arthritis: current therapy and future approaches","volume":"54","author":"Huynh","year":"2015","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7547\/17-076","article-title":"The Reliability of Laboratory Testing in Diagnosing Psoriatic Arthritis: A Case Report","volume":"109","author":"Mahoney","year":"2019","journal-title":"J Am Podiatr Med Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1186\/ar2097","article-title":"HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis","volume":"8","author":"Queiro","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.49.5.318","article-title":"HLA antigens in psoriatic arthritis subtypes of a Spanish population","volume":"49","author":"Lopez-Larrea","year":"1990","journal-title":"Ann Rheumat Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16083","article-title":"HLA-Cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheumat Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: An update for dermatologists","volume":"81","author":"Gottlieb","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.03.016","article-title":"Can magnetic resonance imaging of the hand and wrist differentiate between rheumatoid arthritis and psoriatic arthritis in the early stages of the disease","volume":"42","author":"Narvaez","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018184","article-title":"Dactylitis in psoriatic arthritis: a marker for disease severity","volume":"64","author":"Brockbank","year":"2005","journal-title":"Ann Rheumat Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring methods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheumat Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080491","article-title":"Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis","volume":"36","author":"Lubrano","year":"2009","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/gene.2015.49","article-title":"The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis","volume":"17","author":"Robinson","year":"2016","journal-title":"Genes Immun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.078428","article-title":"On the heritability of psoriatic arthritis. Disease concordance among monozygotic and dizygotic twins","volume":"67","author":"Pedersen","year":"2008","journal-title":"Ann Rheumat Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaut.2017.04.005","article-title":"Lessons learned from twins in autoimmune and chronic inflammatory diseases","volume":"83","author":"Generali","year":"2017","journal-title":"J Autoimmun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.693","article-title":"Genome-wide association analysis identifies three psoriasis susceptibility loci","volume":"42","author":"Stuart","year":"2010","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.689","article-title":"Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2","volume":"42","author":"Ellinghaus","year":"2010","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am J Hum Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.1038\/ncomms7793","article-title":"Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis","volume":"6","author":"Zuo","year":"2015","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/ar3204","article-title":"Promise and pitfalls of the Immunochip","volume":"13","author":"Cortes","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1038\/ncomms8741","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1759720X19886505","DOI":"10.1177\/1759720X19886505","article-title":"The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis","volume":"11","author":"Frischknecht","year":"2019","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205461","article-title":"Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype","volume":"75","author":"Haroon","year":"2016","journal-title":"Ann Rheumat Dis"},{"key":"B39","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.37885","article-title":"Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis","volume":"65","author":"Apel","year":"2013","journal-title":"Arthritis Rheumat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207467","article-title":"ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers","volume":"74","author":"Robinson","year":"2015","journal-title":"Ann Rheumat Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2667","article-title":"Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci","volume":"45","author":"Cortes","year":"2013","journal-title":"Nat Genet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150102","article-title":"Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann Rheumat Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.414","article-title":"Gene expression differences between psoriasis patients with and without inflammatory arthritis","volume":"135","author":"Pollock","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, Proinflammatory, Tissue-Resident Memory Phenotype and Function of Synovial Interleukin-17A+CD8+ T Cells in Psoriatic Arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080458","article-title":"Association of interleukin 23 receptor variants with psoriatic arthritis","volume":"36","author":"Rahman","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"Huffmeier","year":"2010","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-019-0067-y","article-title":"The IL-23\/IL-17 pathway in human chronic inflammatory diseases-new insight from genetics and targeted therapies","volume":"20","author":"Bianchi","year":"2019","journal-title":"Genes Immun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207137","article-title":"RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation","volume":"75","author":"Danks","year":"2016","journal-title":"Ann Rheumat Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0380-2","article-title":"Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions","volume":"102","author":"Paine","year":"2018","journal-title":"Calcified Tissue Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-011-0321-5","article-title":"Role of osteoclasts and interleukin-17 in the pathogenesis of rheumatoid arthritis: crucial \u2018human osteoclastology\u2019","volume":"30","author":"Kotake","year":"2012","journal-title":"J Bone Mineral Metab"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7927.1","article-title":"Recent advances in understanding psoriasis","volume":"5","author":"Eberle","year":"2016","journal-title":"F1000Research"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.415","article-title":"Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL","volume":"132","author":"Ellinghaus","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.17.7806-7819.2004","article-title":"NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity","volume":"24","author":"Fujioka","year":"2004","journal-title":"Mol Cell Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type1 Interferons Potential Initiating Factors Linking Skin Wounds With Psoriasis Pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207187","article-title":"PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus","volume":"74","author":"Bowes","year":"2015","journal-title":"Ann Rheumat Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann Rheumat Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.039164","article-title":"TNFalpha polymorphisms and risk of psoriatic arthritis","volume":"65","author":"Rahman","year":"2006","journal-title":"Ann Rheumat Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.semarthrit.2016.05.012","article-title":"Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same","volume":"46","author":"Coates","year":"2016","journal-title":"Semin Arthritis Rheumat"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(03)00002-9","article-title":"Interleukin-17 family and IL-17 receptors","volume":"14","author":"Moseley","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2017.17037","article-title":"Targeting IL-17 in psoriatic arthritis","volume":"4","author":"Wang","year":"2017","journal-title":"Eur J Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00236","article-title":"Regulation of IL-17 in autoimmune diseases by transcriptional factors and microRNAs","volume":"6","author":"Khan","year":"2015","journal-title":"Front Genet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214138","article-title":"Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis","volume":"78","author":"Wade","year":"2019","journal-title":"Ann Rheumat Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.11.010","article-title":"Osteoclasts in arthritis and Th17 cell development","volume":"11","author":"Okamoto","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5312813","DOI":"10.1155\/2017\/5312813","article-title":"Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms","volume":"2017","author":"Cantatore","year":"2017","journal-title":"BioMed Res Int"},{"key":"B74","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200385","article-title":"IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation","volume":"188","author":"Griffin","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082081","article-title":"Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis","volume":"68","author":"Brentano","year":"2009","journal-title":"Ann Rheumat Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.4.263","article-title":"Differential Th1\/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies","volume":"59","author":"Canete","year":"2000","journal-title":"Ann Rheumat Dis"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheumat Dis"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000147","article-title":"Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis","volume":"27","author":"Mease","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14728214.2015.993378","article-title":"Emerging drugs for the treatment of axial and peripheral spondyloarthritis","volume":"20","author":"Braun","year":"2015","journal-title":"Expert Opin Emerg Drugs"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170144","article-title":"International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting","volume":"44","author":"Coates","year":"2017","journal-title":"J Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew390","article-title":"New GRAPPA and EULAR recommendations for the management of psoriatic arthritis","volume":"56","author":"Coates","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13063-020-4097-6","article-title":"Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)","volume":"21","author":"Mulder","year":"2020","journal-title":"Trials"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13501021","article-title":"Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential","volume":"5","author":"Gottlieb","year":"2013","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheumat Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheumat Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.474","article-title":"OP0054\u2005EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheumat Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.6939","article-title":"AB0928\u2005Ustekinumab and tnf inhibitors in psoriatic arthritis: first follow-up data from a routine care study in 8 european countries (PSABIO)","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheumat Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B96","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheumat Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-eular.2059","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cei.13101","article-title":"Genetics of immune-mediated inflammatory diseases","volume":"193","author":"David","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.596086\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T06:42:39Z","timestamp":1610001759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.596086\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2020.596086"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.596086","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"article-number":"596086"}}